title: Reversal of hepatic steatosis in rats by addition of glucagon to total parenteral nutrition (TPN).
abstract: Infusion of total parenteral nutrition (TPN) with excess carbohydrate calories leads to hepatic steatosis in rats that is associated with an elevated portal insulin/glucagon molar ratio. Previously we have shown that adding glucagon to TPN prevents hepatic steatosis in rats. In this study we attempted to reverse the steatosis by adding glucagon to TPN after 1 week of TPN alone. Adult rats (n = 28) received internal jugular catheters: Group 1 (n = 7), saline (3 cc/h) and chow ad libitum; Group 2 (n = 7), 25% dextrose base TPN solution for 1 week; Group 3 (n = 7), 25% dextrose base TPN for 2 weeks; Group 4 (n = 7), 25% dextrose base TPN for 1 week and then glucagon (15 micrograms/100 g/day) added to TPN for the second week. The infusion rate of TPN was 1.2 ml/100 g/hr (40% kcal greater than control). At 7 days (Group 2) and 14 days (Groups 1, 3, and 4) portal and peripheral venous blood levels were drawn for insulin and glucagon radioimmunoassay, blood glucose determination, and liver function tests; livers were removed for histology and lipid content determination. Blood glucose was equivalent among all groups. Liver function tests were within normal limits. Panlobular vacuolization of the hepatocytes was noted on histology in Groups 2 and 3. Hepatic lipid content was significantly elevated in Group 3. The portal insulin/glucagon molar ratio was increased because of excessive portal venous insulin in Groups 2 and 3 (P less than 0.05 by ANOVA). In contrast, portal venous insulin and the insulin/glucagon molar ratio did not increase in Group 4 and hepatic lipid infiltration was absent when glucagon was added to the TPN solution after 1 week of TPN solution alone. The results suggest that the addition of glucagon to hypertonic dextrose TPN is not only protective in preventing hepatic steatosis, but may reverse steatosis, possibly by increasing hepatic lipid export.
authors.affiliation: Department of Surgery, University of Cincinnati Medical Center, Ohio 45267.
authors.forename: S J
authors.initials: SJ
authors.lastname: Li
authors.forename: M S
authors.initials: MS
authors.lastname: Nussbaum
authors.forename: D W
authors.initials: DW
authors.lastname: McFadden
authors.forename: R
authors.initials: R
authors.lastname: Dayal
authors.forename: J E
authors.initials: JE
authors.lastname: Fischer
mesh_terms: D000818:Animals; D005234:Fatty Liver / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D005934:Glucagon / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism; D008099:Liver / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008111:Liver Function Tests; D008297:Male; D010289:Parenteral Nutrition, Total; D011169:Portal Vein; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D007328:Insulin; D005934:Glucagon